Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
YL202 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| YL202 Dose escalation | EXPERIMENTAL | YL202 will be administrated intravenously (IV) per dose level in which the patients are assigned. |
| Name | Type | Description |
|---|---|---|
| YL202 | DRUG | YL202 is provided as the lyophilized powder, 200 mg/vial. YL202 will be given intravenously once every 3 weeks (Q3W) as a cycle. The initial dose of YL202 will be infused IV into each patient for 90 ±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL202 will be infused IV into each patient for 60 ±10 minutes. |
Inclusion Criteria Patients must satisfy all of the following criteria to be included in the study: 1. Informed of the trial before the start of the trial and voluntarily sign their name and date on the informed consent form 2. Aged ≥18 years 3. Eastern Cooperative Oncology Group performance statu...
Top 20 of 84 competitors
YL202 is an investigational drug being studied for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) and breast cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
YL202 targets HER3, a member of the human epidermal growth factor receptor family. It is an antibody-drug conjugate (ADC) designed to deliver a cytotoxic payload to cancer cells expressing HER3, which is implicated in tumor growth and survival.
YL202 is being developed by BioNTech SE, a biotechnology company traded on the NASDAQ under the ticker symbol BNTX. The company is conducting clinical trials to evaluate the safety and efficacy of YL202 in patients with certain types of cancer.
YL202 is in Phase 1 clinical development. This early-stage trial is designed to assess the safety, tolerability, and preliminary efficacy of the drug in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer. It is not yet approved for commercial use.
YL202 is being evaluated in a Phase 1 clinical trial with the identifier NCT05653752. This study is enrolling approximately 80 patients with locally advanced or metastatic non-small cell lung cancer and breast cancer at sites in the United States and China. The trial is currently active but not recruiting new participants.